TABLE 2.
RE-AIM dimensions with standard definitions, adapted definitions, associated Geisinger DNA screening programs, and data sources.
| Dimensions | Definition | DNA-based population screening definition | Program | Data sources |
|---|---|---|---|---|
| Reach | The absolute number, proportion, and representativeness of individuals willing to participate in a program | The number, proportion, and representativeness of individuals willing to participate in a DNA-based population program that returns genomic information | MyCode (research) | MyCode consent database |
| Effectiveness | The impact of an intervention on important individual outcomes, including potential negative effects, and broader impact including quality of life and economic outcomes; and variability across subgroups (generalizability or heterogeneity of effects) | The impact of returning clinically relevant genetic results to individuals on medical outcomes, psychological and quality of life outcomes, and economic outcomes, including negative effects. Variability across subgroups and including health disparities | MyCode (research) | Review of published MyCode literature |
| Adoption | The absolute number, proportion, and representativeness of people who deliver the program and who are willing to initiate a program | The number of clinical genomic screening tests ordered at pilot sites | Clinical DNA screening pilot | EHR |
| Implementation | Any adaptations made to interventions and implementation strategies | Suggested adaptations to the current clinical pilot to inform future program dissemination | Clinical DNA screening pilot | Semi-structured interviews with clinicians |
| Maintenance | (setting level) the extent to which a program or policy becomes institutionalized or part of the routine organizational practices and policies, and adaptations made to achieve maintenance | (setting level) extent to which MyCode and clinical pilot programs become routine/institutionalized | Not yet assessed | Not applicable |
| (individual level) long term impact (e.g., longitudinal effectiveness, adherence to guidelines) of returning clinically relevant genetic information on individual health outcomes | ||||
| (individual level) the long-term effects of a program on outcomes after a program is completed |